Zai Lab (ZLAB) Projected to Post Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) is expected to be releasing its Q1 2026 results before the market opens on Thursday, May 7th. Analysts expect Zai Lab to post earnings of ($0.5262) per share and revenue of $112.5920 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q1 2026 earning overview page for the latest details on the call scheduled for Thursday, May 7, 2026 at 8:00 AM ET.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings data on Saturday, February 14th. The company reported ($0.50) earnings per share for the quarter. The business had revenue of $127.60 million during the quarter. Zai Lab had a negative return on equity of 22.81% and a negative net margin of 38.15%. On average, analysts expect Zai Lab to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Zai Lab Stock Performance

Zai Lab stock traded down $0.09 during midday trading on Wednesday, hitting $20.89. 260,365 shares of the company were exchanged, compared to its average volume of 742,308. The firm has a market capitalization of $2.37 billion, a PE ratio of -12.98 and a beta of 0.85. Zai Lab has a fifty-two week low of $15.96 and a fifty-two week high of $44.34. The business has a fifty day simple moving average of $20.20 and a two-hundred day simple moving average of $20.23.

Insider Buying and Selling

In other Zai Lab news, CEO Ying Du sold 2,653 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The stock was sold at an average price of $20.45, for a total value of $54,253.85. Following the sale, the chief executive officer directly owned 1,122,626 shares of the company’s stock, valued at approximately $22,957,701.70. This trade represents a 0.24% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Rafael Amado sold 2,739 shares of the firm’s stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $20.45, for a total value of $56,012.55. Following the completion of the sale, the insider directly owned 57,022 shares in the company, valued at approximately $1,166,099.90. The trade was a 4.58% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 46,187 shares of company stock valued at $930,647 in the last 90 days. Corporate insiders own 4.96% of the company’s stock.

Institutional Trading of Zai Lab

A hedge fund recently raised its stake in Zai Lab stock. Royal Bank of Canada grew its stake in Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) by 214.3% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 13,771 shares of the company’s stock after purchasing an additional 9,390 shares during the quarter. Royal Bank of Canada’s holdings in Zai Lab were worth $498,000 as of its most recent SEC filing. Hedge funds and other institutional investors own 41.65% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently commented on ZLAB. UBS Group began coverage on Zai Lab in a report on Wednesday, January 7th. They set a “buy” rating and a $35.00 target price on the stock. Zacks Research lowered shares of Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. Weiss Ratings upgraded shares of Zai Lab from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, April 24th. Cantor Fitzgerald dropped their price target on shares of Zai Lab from $55.00 to $37.00 and set an “overweight” rating on the stock in a research report on Friday, February 27th. Finally, JPMorgan Chase & Co. dropped their price target on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $50.00.

About Zai Lab

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.